Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Advertisement
Andrea B. Apolo, MDTesticular, Penile, and Rare Malignancies | June 12, 2024
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
View More
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 31, 2024
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 31, 2024
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Zachary BessetteTesticular, Penile, and Rare Malignancies | May 6, 2024
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Philippe Spiess, MDTesticular, Penile, and Rare Malignancies | May 7, 2024
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
The primary end point was establishing the risk of relapse connected with both surgical approaches.
Veronica Mollica, MDTesticular, Penile, and Rare Malignancies | April 19, 2024
Dr. Mollica continues her discussion on prognostic factors and clinical outcomes in PSCC.
Veronica Mollica, MDTesticular, Penile, and Rare Malignancies | April 19, 2024
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 19, 2024
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Julian Chavarriaga, MDTesticular, Penile, and Rare Malignancies | April 12, 2024
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 8, 2024
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
Katy MarshallTesticular, Penile, and Rare Malignancies | April 8, 2024
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
Leah LawrenceProstate Cancer Diagnostics | April 8, 2024
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 2, 2024
Survivors with high CIPN experienced more side effects compared to those with low CIPN.
David Ambinder, MDProstate Cancer | March 29, 2024
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
Katy MarshallTesticular, Penile, and Rare Malignancies | March 21, 2024
The Meet-URO 23/I-RARE registry hosts data from patients with rare genitourinary malignancies.
Leah LawrenceProstate Cancer | March 5, 2024
We spoke with clinicians about some of the disparities that exist, why they persist, and what might be done to correct them.
Katy MarshallTesticular, Penile, and Rare Malignancies | February 22, 2024
Researchers analyzed the data of patients with locally advanced PSCC and clinical lymph node metastasis.
Emily MenendezTesticular, Penile, and Rare Malignancies | February 12, 2024
The use of surveillance with repeat CT scans can accurately identify patients with true CS I.
Katy MarshallASCO GU Symposium 2024 | January 24, 2024
The retrospective analysis evaluated 145 plasma samples from 35 patients with stage I, II, and III testicular cancer.
Advertisement
Advertisement
Advertisement